Recent Updates
Recently added Catalysts
KLRS Positive Sentiment

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Tuesday, June 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kalaris Therapeutics has announced an upcoming presentation of its Phase 1a clinical data at the American Society of Retina Specialists. The company is also actively enrolling participants in its Phase 1b/2 clinical trial. This highlights Kalaris's commitment to developing treatments for retinal diseases.
Price reaction · baseline $4.4 (2026-06-22 close) · hit pre-market · clean, no other KLRS news in the window
day 0 close · peak
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Upcoming presentation of Phase 1a clinical data.
  • Active enrollment in Phase 1b/2 clinical trial.
  • Focus on treatments for prevalent retinal diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~25 mo
Minimal dilution risk
Lead asset
Multivirus-specific T cells Dose Level 1
Phase 1 · Viral Infection

Full Press Release Details

BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an upcoming presentation of

Frequently Asked Questions

What is the focus of Kalaris Therapeutics?

Kalaris Therapeutics is focused on developing treatments for prevalent retinal diseases.

When will Kalaris present its clinical data?

Kalaris will present its Phase 1a clinical data at the American Society of Retina Specialists.

Is Kalaris currently enrolling participants?

Yes, Kalaris is actively enrolling participants in its Phase 1b/2 clinical trial.

ShareAdd on Google
Tags: KLRS Viatris Investor Conferences Healthcare Kalaris TH103 Phase 1a clinical trial retinal diseases
Last updated: Jun 23, 2026

Biotech snapshot

Cash runway
$94M liquidity · $4M/mo burn
~25 mo
Minimal dilution risk
Lead asset
Multivirus-specific T cells Dose Level 1Phase 1
Viral Infection →